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ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or 
not “Does the use of intravenous zoledronic acid, in combination with chemotherapy 
regimens, arrest the development and spread of cancer cells to increase disease-free 
survival in breast cancer patients.“ 
 
STUDY DESIGN: Review of three English language primary randomized controlled 
trials published between 2009 and 2010.  
 
DATA SOURCES: Randomized controlled trials and open label, randomized, phase 2 
trial comparing the use of zoledronic acid in combination with chemotherapy to the use 
of chemotherapy alone were found using Medline/PubMed and Cochrane Databases 
 
OUTCOMES MEASURED: The outcomes measured were incidence of metastasis, 
progression of disease, and disease-free survival. Mammography, breast ultrasound, MRI, 
CT scans, and histopathologic studies were used to measure these outcomes after 
treatment was received. 
 
RESULTS: Two randomized controlled trials and one open label, randomized, phase 2 
trial were analyzed in this review. In Aft et al, patients treated with zoledronic acid and 
chemotherapy had fewer detectable disseminated tumor cells at 3 months than at baseline 
(p=0.054). In Coleman et al, the residual invasive tumor size after treatment and resection 
had an adjusted mean difference of 12mm between the two treatment groups (95% CI: 
3.5-20.4mm, p= 0.006). Gnant et al demonstrated that the use of zoledronic acid in 
combination with chemotherapy had a 36% reduction in the risk of disease progression 
and a 35% reduction in the risk of recurrence compared to chemotherapy alone (p= 0.01 
and 0.02, respectively).  
 
CONCLUSION: Based on these three trials, the results of this review were inconclusive. 
The studies analyzed suggest possible anti-tumor effects leading to increases in disease-
free survival. Further research should be aimed at determining a particular chemotherapy 
plus zoledronic acid regimen and a specific patient population for which zoledronic acid 
is most effective.  
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INTRODUCTION 
Breast cancer is the most commonly diagnosed cancer among women and the 
second most common cause of cancer related death in women across the United States1. 
By definition, “breast cancer is a malignant proliferation of epithelial cells lining the 
ducts or lobules of the breast”1. With its primary route of metastasis being via lymphatics, 
aggressive forms of breast cancer can metastasize to the bone, liver, lungs, and brain1.  
 For 2011, it is estimated that 230,480 women with be newly diagnosed with 
breast cancer, with approximately 39, 520 deaths resulting from the disease2. Its 
incidence rate from years 2004 to 2008 was 124:100,000 women per year, with the 
overall median age of diagnosis being 61 years of age2. The overwhelming statistics in 
relation to incidence and mortality have a large impact on the overall economics of breast 
cancer. In 2008, approximately 21.2 million mammograms were ordered from physician 
office visits as screening for breast cancer3. Because of increasing incidence and 
awareness for this disease, the total national expenditure for breast cancer reached an 
estimated $13.9 billion in 2006 and an estimated $631.2 million on research in 2010 3,4. 
In addition to the financial aspects of the disease, a diagnosis of breast cancer has a 
significant impact on the physical and mental health of both the patient and their families.   
 The etiology of breast cancer is multifaceted with several genetic and 
environmental risk factors identified. The BRCA1, BRCA2, and p53 tumor-suppressor 
genes normally function to produce proteins that help to repair damaged DNA1. 
Mutations in these genes cause defective proteins to be produced, which results in 
accelerated and unregulated growth of breast tissue thereby increasing the patient’s risk. 
It has been found that women who inherit a mutated BRCA1 gene have a 60-80% 
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lifetime chance of developing breast cancer1. Environmentally, there are a myriad of non-
modifiable and modifiable risk factors associated with oncogenesis. Age, early onset 
menstruation, late onset menopause, nulliparous, history of radiation therapy, smoking, 
obesity, and hormone replacement therapy are all linked to breast cancer development1.   
 In attempts to treat this disease, researchers are looking to alternative and 
adjunctive therapies to use in combination with the previously implemented 
chemotherapy regimens, surgery, radiation, and hormone treatments. Recent studies 
suggest that the addition of intravenous zoledronic acid (ZA), a third generation 
bisphosphonate, to chemotherapy regimens may provide additional benefit to breast 
cancer patients by arresting tumor growth and preventing the spread of malignant 
cells5,6,7. Although chemotherapy alone has shown to be successful, the addition of 
zoledronic acid promises to increase disease free survival and decrease the incidence of 
metastasis.   
OBJECTIVE  
 The objective of this selective EBM review is to determine whether or not “Does 
the use of intravenous zoledronic acid, in combination with chemotherapy regimens, 
arrest the development and spread of cancer cells to increase disease-free survival in 
breast cancer patients.“  
METHODS 
 All three studies met the criteria for subjects who were female breast cancer 
patients over the age of 18 who where prescribed chemotherapy regimens plus 
intravenous zoledronic acid treatments. One of the studies used was an open label, 
randomized, phase 2 trial which compared neoadjuvant IV zoledronic acid plus 
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epirubicin/docetaxel chemotherapy to epirubicin/docetaxel chemotherapy alone5. The 
other two studies used were randomized control trials; one comparing neoadjuvant IV 
zoledronic acid plus chemotherapy to chemotherapy alone6; the other comparing adjuvant 
IV zoledronic acid plus goserelin plus tamoxifen or anastrozole to goserelin plus 
tamoxifen or anastrozole alone7. 
In the Aft et al study,5 patients received 4 mg of IV zoledronic acid every 3 weeks 
plus epirubicin 75 mg/m2 plus docetaxel 75 mg/m2 every 3 weeks for 1 year. In the 
randomized control trial by Coleman et al,6 patients received 6 doses of 4 mg IV 
zoledronic acid every 3-4 weeks in combination with their chemotherapy treatment. In 
the Gnant et al study,7 patients received 3.6 mg of subcutaneous goserelin plus either 
tamoxifen 20 mg per day orally or anastrozole 1 mg per day orally with or without 4 mg 
of IV zoledronic acid every 6 months.  
 A detailed search was completed by the author using the following search 
engines: Medline/PubMed, Cochrane Database of Randomized Controlled Trials, and 
Cochrane Database of Systemic Reviews. The key words “breast cancer” “breast 
neoplasm” and “zoledronic acid” were used. All articles were published in the English 
language in peer reviewed journals. One meta-analysis exists on this topic and was last 
updated in 2010. Gnant et al was published in 2009 but was not included in this meta-
analysis. No information from the meta-analysis will be used as part of this paper. All 
other articles used were published after March of 2010.  The articles were selected based 
on their relevance and the importance of the outcome to the patient (POEMS). Studies 
that were included were those that were randomized, controlled, not included in a meta-
analysis or were published after March 2010, and based on patient oriented outcomes. 
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Studies excluded were those that included male patients, prior history of neoplasm, 
pregnancy, or contraindications to chemotherapy or zoledronic acid. Statistics utilized in 
these studies were p-values with a value <0.05 being statistically significant, 95% 
confidence intervals, numbers needed to treat (NNT), and numbers needed to harm 
(NNH). Table 1 outlines the demographics and characteristics included in these studies. 
Table 1: Demographics and Characteristics of Included Studies  
Study Type # pts Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Aft, 
2010 
Open 
label, 
random
ized, 
phase 2 
trial 
120 29-68 Women with 
clinical stage II-
III newly 
diagnosed 
breast cancer, 
Staged > T2 
and/or > N1, 
ECO Group 
performance of 
0 or 1, Normal 
cardiac, renal, 
and liver 
function 
Evidence of 
distant 
metastasis, 
Prior 
malignancy, 
Disorders of 
the heart, 
liver, or 
kidneys, 
Pregnancy, 
Women < 
18 years old 
 
31 Patients 
received 4 mg 
of IV ZA 
every 3 weeks 
for 1 year plus 
prescribed 
chemotherapy 
treatment 
(epirubicin 75 
mg/m2 plus 
docetaxel 75 
mg/m2 every 
3 weeks) 
Cole
man, 
2010 
RCT 205 41-57 Women 
receiving 
neoadjuvant 
chemotherapy, 
Staged > T3 
and/or > N1, 
Scheduled to 
receive surgery 
and/or radical 
radiotherapy, 
curative intent 
within 6 months 
of initiating 
therapy 
 
Prior 
malignancy,
Women < 
18 years old 
10 Patients 
received 6 
doses of 4 mg 
IV ZA every 
3-4 weeks in 
combination 
with their 
neoadjuvant 
chemotherapy 
treatment, 
followed by 
surgical 
resection 
tumor 
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Gnant
, 2009 
RCT 1803 25-57 Premenopausal 
women, surgery 
for stage I or II 
breast cancer, 
Estrogen 
receptor 
positive and/or 
progesterone 
receptor 
positive, Less 
than 10 positive 
lymph nodes, 
Prescribed 
goserelin for 
chemotherapy  
 
Stage T1a, 
T4d, or yT4, 
Prior history 
of 
neoplasm, 
Preoperative 
radiation, 
Pregnancy, 
Lactation, 
Contraindic
ations for 
study 
medications 
 
150 Patients 
received 
goserelin plus 
tamoxifen or 
anastrozole 
with ZA (4 
mg every 6 
months) for 3 
years 
 
 
OUTCOMES MEASURED 
 The outcomes measured were those of patient oriented evidence that matters 
(POEMS), which includes incidence of metastasis, progression of disease, and disease-
free survival. Mammography, breast ultrasound, MRI, CT scans, and histopathologic 
studies were used to measure these outcomes after treatment was received 5,6,7.  
RESULTS 
 Two randomized controlled trials and one open label, randomized, phase 2 trial 
are analyzed in this review. All participants are female patients diagnosed with breast 
cancer and prescribed a chemotherapy regimen without or without zoledronic acid 
treatment. The results were presented in dichotomous form in the Aft et al5 and Gnant et 
al7 studies, but presented as continuous data in the Coleman et al study6.  
 The Aft et al study assessed the incidence of detectable disseminated tumor cells 
(DTC) in the bone marrow of breast cancer patients three months after treatment5. In the 
control group, 28 of the 58 patients had DTCs at baseline compared to 26 of 60 patients 
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in the chemotherapy plus zoledronic acid group. After three months and four cycles of 
treatment, 25 of 53 patients in the control group had detectable DTCs compared to 17 of 
56 patients in the zoledronic acid group (p=0.054). However, of the patients without 
detectable DTCs at baseline, 15 of 25 patients in the control group remained negative 
compared to 27 of 31 patients in the zoledronic acid group (p=0.030)  (Table 2)5.  
Table 2- Efficacy of chemotherapy plus zoledronic acid in reduction of disseminated 
tumor cells compared to chemotherapy alone 
 Chemotherapy Alone Chemotherapy + ZA p-value 
Baseline DTCs 28/58   (48.3%) 26/60   (43.3%) - 
No Baseline DTCs 30/30 34/34 - 
Evidence of DTCs at 
3 months 
25/53   (47.2%) 17/56   (30.4%) 0.054 
DTC negative at 
baseline and 3 
months 
15/25   (60%) 27/31   (87.1%) 0.030 
 
The control event rate (CER) was determined as those who had detectable DTCs 
after three months of the treatment without zoledronic acid. The CER was calculated to 
be 47.1%. The experimental event rate (EER) was determined as the number of patients 
who had detectable DTCs with zoledronic acid treatment. The EER was found to be 
30.4%. From this data, the absolute benefit increase (ABI) was -16.7% with a number 
needed to treat (NNT) of -6 and a number needed to harm (NNH) of 13 (Table 6)5,7.  
 Coleman et al assessed the residual invasive tumor size in breast cancer patients 
treated with neoadjuvant therapy6. Patients in this study had primary end points evaluated 
by surgical resection specimens. The data was presented as continuous data that could not 
be converted into a dichotomous format. There were 182 patients assessed for residual 
invasive tumor size (RITS), the primary end point, in both groups. Adjusted means were 
calculated taking into account biological and clinical factors known to affect tumor 
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response. The adjusted means for the control group and the chemotherapy plus zoledronic 
acid group (CT + ZA) were 27.4 mm and 15.5 mm, respectively, revealing a difference in 
means of 12 mm (95% CI 3.5-20.4mm, p=0.0059) (Table 3)6. 
Table 3 – Efficacy of chemotherapy plus zoledronic acid on residual invasive tumor 
size compared to chemotherapy alone 
 CT Alone CT + ZA Estimate s.e. 95% CI p-value 
RITS (adjusted 
means) 
27.4 mm 15.5 mm 12 4.3 (3.5, 20.4) 0.0059 
 
The Gnant et al study assessed the effects of chemotherapy plus zoledronic acid 
on disease-free and recurrence-free survival7. A median follow up period of 47.8 months 
was used to assess the status of the 1803 patients followed in this study. In the 
experimental group, 845 of the 899 patients (94.0%) were free of disease compared to 
821 of the 904 (90.8%) patients in the control group (p=0.01). Similarly, 845 of the 899 
(94.0%) patients in the experimental group were recurrence-free as compared to the 822 
of the 904 patients (90.9%) in the control group at the same 47.8 month follow up period 
(p=0.01) (Table 4)7. For disease-free survival, the absolute benefit increase (ABI) was 
3.2%, with a numbers needed to treat (NNT) of 32 patients, and a numbers needed to 
harm (NNH) of -32 patients. For recurrence-free survival, the ABI was 3.1%, the NNT 
was 33 patients, and the NNH was -33 patients (Table 6)5,7. Using Cox analysis, patients 
who received zoledronic acid had a 36% reduction in the risk of disease progression and 
a 35% reduction in the risk of recurrence compared to the control group (Table 4)7.   
Table 4- Efficacy of Zoledronic Acid on Disease Free Survival 
 Chemotherapy 
Alone 
Chemotherapy 
plus ZA 
p-value % Risk 
Reduction  
Cox     
p-value 
Disease-Free 
Survival 
821/904   
(90.8%) 
845/899   
(94.0%) 
0.01 36%  0.01 
Recurrence-
Free Survival  
822/904   
(90.9%) 
845/899   
(94.0%) 
0.01 35% 0.02 
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The primary end point for the Gnant et al7 study was disease-free survival. This 
was defined as “a period of time beginning at randomization to the occurrence of one or 
more of the following: a local or regional recurrence, cancer in the contralateral breast, 
distant metastasis, second primary carcinoma, or death from any cause.” As outlined in 
Table 5 below, the addition of zoledronic acid had fewer events in all categories.  
Table 5- Events in the Intention-to-Treat Population 
Event Chemotherapy Alone Chemotherapy plus ZA 
Locoregional Recurrence 20 10 
Distant Metastasis 41 29 
Contralateral Breast Cancer  10 6 
Secondary Primary Cancer 10 9 
Death  26 16 
 
As illustrated below in Table 6, a negative NNT was calculated for the Aft et al5 
trial due to the fact that the study is measuring the incidence of metastasis. This negative 
NNT suggests that for every six patients treated with zoledronic acid there is one less 
patient who will experience metastatic disease in the experimental group when compared 
to the control group. Similarly, the data provided in both the Aft et al5 and the Gnant et 
al7 studies allowed for a numbers needed to harm to be calculated. In the Aft et al5 study, 
for every 13 people treated with zoledronic acid, 1 patient would be harmed in the 
experimental group compared to the control group. In the Gnant et al7 trial, negative 
numbers needed to harm were obtained for both disease-free and recurrence-free survival. 
For disease-free survival, this suggests that for every 32 patients treated with zoledronic 
acid in the experimental group, one patient in the control group will be harmed. Likewise, 
for recurrence-free survival, for every 33 patients treated with zoledronic acid in the 
experimental group, one patient in the control group will be harmed. In these instances, 
harm refers to disease progression or recurrence.  
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Table 6- Comparison of Dichotomous Data  
Study CER EER ABI NNT NNH 
Aft, et al      
 Reduction of DTCs 47.1% 30.4% -16.7% -6 13 
Gnant, et al      
 Disease-Free Survival 90.8% 94% 3.2% 32 -32 
 Recrrence-Free Survival  90.9% 94% 3.1% 33 -33 
 
Because of the condition and treatments analyzed in these studies, the safety and 
health of the patients involved were closely monitored throughout the trials. In the Aft et 
al5 trial, a safety analysis was performed on 119 patients using the National Cancer 
Institute Common Terminology Criteria for Adverse Events version 3.0. The most 
common adverse events noted were infection, thrombosis/DVT, and neutropenic fever. In 
the Coleman et al6 trial, there were 63 serious adverse events (SAE) reported, 36 events 
in the chemotherapy alone group versus 27 in the chemotherapy plus zoledronic acid 
group. The most commonly reported SAE was neutropenic sepsis. In the Gnant et al7 
trial, the most commonly reported adverse events were arthralgia, bone pain, and fever. 
The methods used for reporting adverse events in the Coleman et al and Gnant et al trials 
were not noted.  
Table 7- Adverse Events Across Trials (number of patients monitored) 
 Aft et al (119) Coleman et al (205) Gnant et al (1803) 
 CT alone CT + 
ZA 
CT alone CT + 
ZA 
CT alone CT + ZA 
Adverse Event  
Infection 6 5   
Thrombosis/DVT 2 5   
Fever 2 3  20 80 
Neutropenic Sepsis  16 14  
Arthralgia   164 215 
Bone Pain   222 317 
 
 
Colasurdo, Zoledronic Acid & Breast Cancer  10 
DISCUSSION 
In the RCT conducted by Aft et al, the use of zoledronic acid in combination with 
epirubicin and docetaxel did not have a statistically significant impact on reducing 
detectable DTCs after three months of treatment5. It did, however, show statistically 
significant results for patients who were initially DTC negative that remained DTC 
negative after treatment5. Unfortunately, this was not the aim of this study and therefore 
requires further investigation. Even though the results were not statistically significant, 
patients treated with the combination of chemotherapy and zoledronic acid had fewer 
detectable DTCs at 3 months than at baseline.  
Results collected by Coleman et al found that the residual invasive tumor size was 
significantly influenced by the use of zoledronic acid in combination with chemotherapy 
treatments6. Considering residual invasive tumor size is the estimated amount of tumor 
remaining post surgical resection, lower values suggest longer disease-free survival for 
these patients6. As the primary end point, the comparison between treatment groups 
revealed a mean difference of 12mm, with the lowest values in the experimental group, 
thus showing a positive benefit to adding zoledronic acid to the chemotherapy regimen.  
Furthermore, in the Gnant et al study, statistically significant data was collected 
supporting the use of zoledronic acid as an adjunctive therapy to increase disease-free 
and recurrence-free survival7. The outcome of this study also identified a possible patient 
population for which zoledronic acid is beneficial; those with low to intermediate risk, 
endocrine-responsive early breast cancer tumors7.   
Unfortunately, many limitations exist in this patient population, which affect the 
validity of these results and thus the outcome of this review. Multiple chemotherapy 
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regimens were used, both premenopausal and menopausal patients were analyzed, and 
various outcomes were measured to assess the effects of zoledronic acid as an adjunctive 
therapy for breast cancer patients. Additionally, the outcomes were measured using 
mammography, breast ultrasound, MRI, CT, and histopathologic studies. Limitations of 
these studies include interpretation of the data, specifically in regards to the presence of 
DTCs in Aft et al5, and in the inter-pathologist variation as noted in Coleman et al6.  
Zoledronic acid is a third-generation bisphosphonate currently used as treatment 
for osteoporosis in men and postmenopausal women, hypercalcemia of malignancy 
(HCM), and bone metastases caused by solid tumors8. It primarily works to prevent bone 
resorption by inhibiting osteoclast activity and promoting osteoclast apoptosis8. The FDA 
approved “Zometa” in 2001 as a treatment for HCM and oncology-related indications8. In 
2007, the same drug was approved under the name “Reclast” for the treatment of 
osteoporosis and Paget’s Disease8.  
CONCLUSION 
Based on the three trials analyzed in this review, the evidence is inconclusive if 
the use of zoledronic acid in combination with chemotherapy arrests the development and 
spread of cancer cells to increase disease-free survival. As discussed, there is mounting 
evidence in favor of this adjunctive therapy with results trending in favor of its antitumor 
and anti-metastatic effects.   
In addition to larger patient populations evaluated over longer periods of time, 
future trials would benefit from using a single type of chemotherapy, be exclusive of 
premenopausal or postmenopausal patients and a specified hormone-receptor status, and 
address an optimal dosing schedule for zoledronic acid administration. 
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